Sep 2026· Naunyn-Schmiedeberg's Archives of Pharmacology· 0 citations· 89 references
Medicine
TL;DR
VIN attenuated changes in the AMPK/SIRT1 and PI3K/Akt axes, MAPK, TLR4/NF-κB p65 signaling, as well as NLRP3-related signaling in a dose-responsive manner, and its cardioprotective effects were accompanied by improved redox balance, increased AMPK/SIRT1 and PI3K/Akt expression, reduced phosphorylated MAPK abundance, and lower inflammatory and apoptosis-
Linagliptin demonstrates potent cardioprotective effects against cisplatin-induced toxicity, primarily through modulation of the SIRT1/AMPK/Nrf2 signaling pathway, thereby resulting in reduced oxidative stress and inflammation.
M. Alsugoor, N. Alsuhaymi, Bassim M. S. A. Mohamed et al.· Drug and chemical toxicology...· 0 citations
Buspirone pretreatment mitigated CPA-induced renal dysfunction, accompanied by increased miR-205 expression, reduced EGLN2 expression, enhanced Nrf2-associated antioxidant defenses, and attenuation of ER stress, inflammation, and apoptosis, thereby preserving renal function and tissue integrity.
Ahmed M. El-Dessouki, A. Alrashidi, Mohammad I Jumaa et al.· Frontiers in Pharmacology· 0 citations
Hepatic encephalopathy (HE) is a neuropsychiatric disorder associated with oxidative stress, neuroinflammation, and hyperammonaemia secondary to hepatic dysfunction. This study aimed to investigate dapagliflozin's effects (DAPA) against HE induced by thioacetamide (TAA) in rats and to elucidate the roles of the extrace...
Hadir Farouk, Salma A. El-Marasy, M. S. Khattab et al.· Toxicology Mechanisms and Me...· 0 citations
BACKGROUND
Isotretinoin is a widely prescribed retinoid for severe acne but is limited by dose-dependent hepatotoxicity. Tranexamic acid (TXA), an antifibrinolytic agent with emerging anti-inflammatory and antioxidant effects, may offer hepatoprotective potential. Aim: This study evaluated whether TXA mitigates isotret...
Abdullah Alkhammash, H. Hagar, Hatem Ali Ahmed Abdelmottaleb et al.· Immunopharmacology and immun...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.